| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99444 |
|
7,539 |
1,924 |
$429K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
11,138 |
8,290 |
$258K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,424 |
3,637 |
$104K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
578 |
562 |
$60K |
| 99421 |
|
2,595 |
659 |
$41K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
483 |
431 |
$17K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
205 |
173 |
$8K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
31 |
31 |
$8K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
260 |
254 |
$8K |
| 95927 |
|
363 |
363 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
754 |
677 |
$6K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
292 |
53 |
$5K |
| 95943 |
|
363 |
363 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
203 |
169 |
$4K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
41 |
40 |
$3K |
| G0179 |
Physician or allowed practitioner re-certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and allowed practitioners to affirm the initial implementation of the plan of care |
973 |
972 |
$2K |
| 93922 |
|
361 |
361 |
$1K |
| 0071A |
|
26 |
26 |
$960.00 |
| 0001A |
|
31 |
31 |
$858.00 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14 |
14 |
$723.96 |
| 0004A |
|
17 |
17 |
$638.00 |
| 93000 |
|
120 |
117 |
$531.70 |
| 0002A |
|
20 |
20 |
$514.00 |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
33 |
33 |
$433.07 |
| 99215 |
Prolong outpt/office vis |
41 |
39 |
$418.38 |
| 0072A |
|
14 |
14 |
$400.00 |
| 90686 |
|
52 |
52 |
$372.57 |
| 99091 |
|
813 |
767 |
$312.86 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
44 |
40 |
$156.66 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
223 |
211 |
$149.55 |
| 81002 |
|
250 |
210 |
$137.74 |
| S8301 |
Infection control supplies, not otherwise specified |
26 |
24 |
$115.49 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
83 |
77 |
$34.25 |
| 82962 |
|
966 |
795 |
$25.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
31 |
30 |
$7.01 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
13 |
13 |
$0.21 |
| 91301 |
|
72 |
71 |
$0.02 |
| 95117 |
|
62 |
24 |
$0.00 |
| 3017F |
|
303 |
268 |
$0.00 |
| G8754 |
Most recent diastolic blood pressure < 90 mmhg |
4,680 |
3,367 |
$0.00 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
767 |
706 |
$0.00 |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
92 |
91 |
$0.00 |
| 3044F |
|
47 |
40 |
$0.00 |
| 1036F |
|
888 |
810 |
$0.00 |
| G9717 |
Documentation stating the patient has had a diagnosis of bipolar disorder |
246 |
217 |
$0.00 |
| 0509F |
|
126 |
123 |
$0.00 |
| 91307 |
|
40 |
40 |
$0.00 |
| 1124F |
|
629 |
578 |
$0.00 |
| G8752 |
Most recent systolic blood pressure < 140 mmhg |
3,480 |
2,631 |
$0.00 |
| 4040F |
|
487 |
443 |
$0.00 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
6,112 |
4,369 |
$0.00 |
| G8482 |
Influenza immunization administered or previously received |
597 |
526 |
$0.00 |
| G8753 |
Most recent systolic blood pressure >= 140 mmhg |
1,142 |
955 |
$0.00 |
| G8483 |
Influenza immunization was not administered for reasons documented by clinician (e.g., patient allergy or other medical reasons, patient declined or other patient reasons, vaccine not available or other system reasons) |
372 |
361 |
$0.00 |
| 3045F |
|
41 |
34 |
$0.00 |
| G9899 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed |
86 |
83 |
$0.00 |
| G8399 |
Patient with documented results of a central dual-energy x-ray absorptiometry (dxa) ever being performed |
169 |
158 |
$0.00 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
31 |
31 |
$0.00 |
| 3046F |
|
462 |
427 |
$0.00 |
| 91300 |
|
69 |
69 |
$0.00 |
| G0246 |
Follow-up physician evaluation and management of a diabetic patient with diabetic sensory neuropathy resulting in a loss of protective sensation (lops) to include at least the following: (1) a patient history, (2) a physical examination that includes: (a) visual inspection of the forefoot, hindfoot and toe web spaces, (b) evaluation of protective sensation, (c) evaluation of foot structure and biomechanics, (d) evaluation of vascular status and skin integrity, and (e) evaluation and recommendation of footwear, and (3) patient education |
26 |
26 |
$0.00 |
| G8400 |
Patient with central dual-energy x-ray absorptiometry (dxa) results not documented, reason not given |
19 |
14 |
$0.00 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
94 |
92 |
$0.00 |
| G9900 |
Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results were not documented and reviewed, reason not otherwise specified |
21 |
19 |
$0.00 |
| 4004F |
|
32 |
22 |
$0.00 |